BPC November 16 update

Molecular MOLN DSMB negative assessment; Kezar KZR Phase 2 data

Pre-Market Updates

Molecular Partners AG (NASDAQ: MOLN) announced the outcome of a planned futility analysis by the Data and Safety Monitoring Board (DSMB) of its Phase 3 ACTIV-3 study of ensovibep to treat mild to moderate COVID-19. The DSMB meeting resulted in an assessment that the trial has not met the thresholds required to continue enrollment of adults with COVID-19 in the hospitalized setting.

Kezar Life Sciences, Inc. (NASDAQ: KZR) continues to trade up after it releases interim results from its Phase 2 portion of its MISSION trial of KZR-616 to treat lupus nephritis (LN) during the after-hours session yesterday. 3 of 5 patients had a 50% or greater reduction in UPCR, and 4 patients reported a clinically meaningful reduction in proteinuria to less than 0.8 UPCR.

Exicure, Inc. (NASDAQ: XCUR) announced that it has filed a Form 12b-25 with the U.S. Securities and Exchange Commission in connection with its Quarterly Report on Form 10-Q for the period ended September 30, 2021.

Liminal BioSciences Inc. (NASDAQ: LMNL) reported its third-quarter earnings during the after-hours session yesterday. Liminal reported a net income of $82.3 million compared to a net loss of $23.3 million year over year.

Evofem Biosciences, Inc. (NASDAQ: EVFM) reported its third-quarter earnings during the after-hours session yesterday. Evofem reported losses of $0.48 per share which missed the estimate of $0.29 by 65.52%. Evofem reported $1.71 million in sales in the third quarter. This is a 515.83% increase over sales of $278,000 in the same period last year.

Optinose (NASDAQ: OPTN) announced a public offering of 25,000,000 shares of its common stock at a public offering price of $1.60 per share, for gross proceeds of $40 million.

Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) reported third-quarter earnings noting $2.20 million in sales. This is a 37.14% decrease over sales of $3.50 million in the same period last year.

Pre-Market Advancers

CompanyPriceChange
PTN
Palatin Technologies Inc.
$0.79+0.2324  +41.68%
STSA
Satsuma Pharmaceuticals Inc.
$5.96+0.71  +13.52%
BYSI
BeyondSpring Inc.
$16.25+1.9  +13.24%
ACHL
Achilles Therapeutics plc
$5.39+0.55  +11.36%
OGEN
Oragenics Inc.
$0.60+0.0488  +8.87%
DRMA
Dermata Therapeutics Inc.
$2.93+0.23  +8.52%
UNCY
Unicycive Therapeutics Inc.
$3.16+0.24  +8.22%
WDNA
WisdomTree BioRevolution Fund
$26.00+1.8493  +7.66%
LOGC
LogicBio Therapeutics Inc.
$3.15+0.21  +7.14%
URGN
UroGen Pharma Ltd.
$13.00+0.86  +7.08%

Pre-Market Decliners

CompanyPriceChange
NAVB
Navidea Biopharmaceuticals Inc.
$1.15-0.15  -11.54%
IKT
Inhibikase Therapeutics Inc.
$1.91-0.15  -7.28%
PSTI
Pluristem Therapeutics Inc.
$2.52-0.17  -6.32%
BPTS
Biophytis SA
$5.40-0.36  -6.25%
APVO
Aptevo Therapeutics Inc.
$12.26-0.81  -6.20%
ANGN
Angion Biomedica Corp.
$3.54-0.2099  -5.60%
PBLA
Panbela Therapeutics Inc.
$1.86-0.11  -5.58%
VLON
Vallon Pharmaceuticals Inc.
$5.05-0.26  -4.90%
RVPH
Reviva Pharmaceuticals Holdings Inc.
$3.60-0.18  -4.76%
CRNX
Crinetics Pharmaceuticals Inc.
$23.25-1.15  -4.71%